33.78
0.02 (0.06%)
| Previous Close | 33.76 |
| Open | 33.68 |
| Volume | 155,113 |
| Avg. Volume (3M) | 2,212,579 |
| Market Cap | 5,359,724,544 |
| Price / Earnings (TTM) | 88.89 |
| Price / Earnings (Forward) | 42.92 |
| Price / Sales | 13.63 |
| Price / Book | 21.04 |
| 52 Weeks Range | |
| Earnings Date | 4 Nov 2025 |
| Profit Margin | 10.13% |
| Operating Margin (TTM) | 7.13% |
| Diluted EPS (TTM) | 0.250 |
| Quarterly Revenue Growth (YOY) | 90.40% |
| Quarterly Earnings Growth (YOY) | -96.60% |
| Total Debt/Equity (MRQ) | 107.29% |
| Current Ratio (MRQ) | 4.02 |
| Operating Cash Flow (TTM) | -61.02 M |
| Levered Free Cash Flow (TTM) | -87.64 M |
| Return on Assets (TTM) | 7.26% |
| Return on Equity (TTM) | 19.70% |
Market Trend
| Short Term | Medium Term | ||
| Industry | Biotechnology (US) | Mixed | Mixed |
| Biotechnology (Global) | Mixed | Mixed | |
| Stock | TG Therapeutics, Inc. | Bullish | Bullish |
AIStockmoo Score
| Analyst Consensus | 5.0 |
| Insider Activity | NA |
| Price Volatility | 1.0 |
| Technical Moving Averages | -3.5 |
| Technical Oscillators | -0.5 |
| Average | 0.50 |
|
TG Therapeutics Inc is a fully integrated, commercial-stage, biopharmaceutical company focused on the acquisition, development, and commercialization of novel treatments for B-cell diseases. The company has received approval from the U.S. Food and Drug Administration (FDA) for BRIUMVI (ublituximab-xiiy) for the treatment of adult patients with relapsing forms of multiple sclerosis (RMS). In addition, it is developing TG-1701 (BTK inhibitor), Azer-Cel (allogeneic CD19 CAR T), and TG-1801 (anti-CD47/CD19 bispecific mAb) for B-cell disorders, which are under Phase 1 trials. Geographically, the company generates a majority of its revenue selling BRIUMVI in the United States, with the rest coming from sales in other countries. |
|
| Sector | Healthcare |
| Industry | Biotechnology |
| Investment Style | Small Growth |
| % Held by Insiders | 9.74% |
| % Held by Institutions | 63.22% |
Ownership
| Name | Date | Shares Held |
|---|---|---|
| Soleus Capital Management, L.P. | 30 Jun 2025 | 2,243,935 |
| Pictet Asset Management Holding Sa | 30 Jun 2025 | 1,907,491 |
| Hood River Capital Management Llc | 30 Jun 2025 | 1,567,506 |
| 52 Weeks Range | ||
| Price Target Range | ||
| High | 60.00 (HC Wainwright & Co., 77.62%) | Buy |
| Median | 57.50 (70.22%) | |
| Low | 55.00 (B. Riley Securities, 62.82%) | Buy |
| Average | 57.50 (70.22%) | |
| Total | 2 Buy | |
| Avg. Price @ Call | 34.40 | |
| Firm | Date | Target Price | Call | Price @ Call |
|---|---|---|---|---|
| HC Wainwright & Co. | 06 Oct 2025 | 60.00 (77.62%) | Buy | 36.76 |
| B. Riley Securities | 17 Sep 2025 | 55.00 (62.82%) | Buy | 32.04 |
No data within this time range.
The support, resistance and trendline levels presented has been generated by an artificial intelligence (AI) model and should be interpreted with caution.
Portfolio
| Realized Profit | - |
| Unrealized Profit | - |
| Dividend Received 2025 | - |
| Total Profit | - |
| Avg. Return | - |
| Quantity (Buy) | - |
| Avg. Price (Buy) | - |
| Quantity (Sold) | - |
| Avg. Price (Sold) | - |